Amicus Therapeutics (NASDAQ:FOLD) saw its excellent 2012 performance cut in half today, as shares that had been up 70% for the year fell 45% in a single day. The fall came on news that the company's lead drug, called migalastat, which was designed to treat Fabry disease, failed to meet its primary endpoint in its phase 3 trial. In this video, Motley Fool health-care analysts Max Macaluso and Brenton Flynn break down this news, and discuss where Amicus and GlaxoSmithKline (NYSE:GSK), with whom Amicus was partnered on the compound, can go from here.
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.